Lista de obras - Camilla Evangelisti - Dominio Público Uruguay

Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 against T-cell acute lymphoblastic leukemia.

artículo científico publicado en 2010

Advances in targeting signal transduction pathways

artículo científico publicado en 2012

Advances in understanding the acute lymphoblastic leukemia bone marrow microenvironment: From biology to therapeutic targeting

artículo científico

Alteration of Akt activity increases chemotherapeutic drug and hormonal resistance in breast cancer yet confers an achilles heel by sensitization to targeted therapy

artículo científico publicado en 2008

Autophagy in acute leukemias: a double-edged sword with important therapeutic implications

artículo científico publicado en 2015

Current treatment strategies for inhibiting mTOR in cancer

artículo científico publicado en 2014

Cytotoxic activity of the novel Akt inhibitor, MK-2206, in T-cell acute lymphoblastic leukemia.

artículo científico publicado en 2012

DGKζ is degraded through the cytoplasmic ubiquitin-proteasome system under excitotoxic conditions, which causes neuronal apoptosis because of aberrant cell cycle reentry.

artículo científico publicado en 2012

GSK-3β: a key regulator of breast cancer drug resistance

scientific article published on 04 February 2014

Identification of a functional nuclear export sequence in diacylglycerol kinase-zeta.

artículo científico publicado en 2010

Improving nelarabine efficacy in T cell acute lymphoblastic leukemia by targeting aberrant PI3K/AKT/mTOR signaling pathway

scientific article published on 24 October 2016

Increased NGAL (Lnc2) expression after chemotherapeutic drug treatment.

artículo científico publicado en 2012

Modulation of TGFbeta 2 levels by lamin A in U2-OS osteoblast-like cells: understanding the osteolytic process triggered by altered lamins

artículo científico publicado en 2015

Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response

artículo científico publicado en 2012

Nuclear diacylglycerol kinase-zeta is a negative regulator of cell cycle progression in C2C12 mouse myoblasts

artículo científico publicado en 2007

Nuclear inositol lipid metabolism: more than just second messenger generation?

artículo científico publicado en 2005

Nuclear phosphoinositides and their roles in cell biology and disease

artículo científico publicado en 2011

PI3K isoform inhibition associated with anti Bcr-Abl drugs shows in vitro increased anti-leukemic activity in Philadelphia chromosome-positive B-acute lymphoblastic leukemia cell lines

artículo científico publicado en 2017

PI3K/AKT/mTORC1 and MEK/ERK signaling in T-cell acute lymphoblastic leukemia: new options for targeted therapy

scientific article published on 01 January 2012

Phosphatidylinositol 3-kinase inhibition potentiates glucocorticoid response in B-cell acute lymphoblastic leukemia

artículo científico publicado en 2017

Phosphoinositide 3-kinase/Akt signaling pathway and its therapeutical implications for human acute myeloid leukemia.

artículo científico publicado en 2006

Potential therapeutic effects of the MTOR inhibitors for preventing ageing and progeria-related disorders

artículo científico publicado en 2016

Preclinical testing of the Akt inhibitor triciribine in T-cell acute lymphoblastic leukemia.

artículo científico publicado en 2011

Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance

artículo científico publicado en 2012

Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health

artículo científico publicado en 2011

Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging

artículo científico publicado en 2011

Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance

artículo científico publicado en 2007

Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy.

artículo científico publicado en 2011

Subnuclear localization and differentiation-dependent increased expression of DGK-zeta in C2C12 mouse myoblasts.

artículo científico publicado en 2006

Synergistic cytotoxic effects of bortezomib and CK2 inhibitor CX-4945 in acute lymphoblastic leukemia: turning off the prosurvival ER chaperone BIP/Grp78 and turning on the pro-apoptotic NF-κB.

artículo científico publicado en 2015

TIS21/BTG2/PC3 and cyclin D1 are key determinants of nuclear diacylglycerol kinase-zeta-dependent cell cycle arrest

artículo científico publicado en 2009

Targeted inhibition of mTORC1 and mTORC2 by active-site mTOR inhibitors has cytotoxic effects in T-cell acute lymphoblastic leukemia.

artículo científico publicado en 2011

Targeting Wnt/β-catenin and PI3K/Akt/mTOR pathways in T-cell acute lymphoblastic leukemia

artículo científico publicado en 2020

Targeting phosphatidylinositol 3-kinase signaling in acute myelogenous leukemia

artículo científico publicado en 2013

Targeting signaling pathways in T-cell acute lymphoblastic leukemia initiating cells

artículo científico

Targeting the PI3K/AKT/mTOR signaling network in acute myelogenous leukemia

artículo científico publicado en 2009

Targeting the RAF/MEK/ERK, PI3K/AKT and p53 pathways in hematopoietic drug resistance.

artículo científico publicado en 2007

Targeting the cancer initiating cell: the ultimate target for cancer therapy.

artículo científico publicado en 2012

Targeting the liver kinase B1/AMP-activated protein kinase pathway as a therapeutic strategy for hematological malignancies

artículo científico

Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway

artículo científico publicado en 2011

The Cutting Edge: The Role of mTOR Signaling in Laminopathies

scientific article published on 15 February 2019

The Unfolded Protein Response: A Novel Therapeutic Target in Acute Leukemias

artículo científico publicado en 2020

The emerging multiple roles of nuclear Akt

artículo científico publicado en 2012

The emerging role of the phosphatidylinositol 3-kinase/ akt/mammalian target of rapamycin signaling network in cancer stem cell biology

artículo científico publicado en 2010

The emerging role of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin signaling network in normal myelopoiesis and leukemogenesis.

artículo científico publicado en 2010

The insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 induces apoptosis in acute myeloid leukemia cells exhibiting autocrine insulin-like growth factor-I secretion

scientific article published on 15 March 2007

The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients.

artículo científico publicado en 2010

Therapeutic Targeting of mTOR in T-Cell Acute Lymphoblastic Leukemia: An Update

artículo científico publicado en 2018

Therapeutic potential of targeting mTOR in T-cell acute lymphoblastic leukemia (review).

artículo científico

Therapeutic targeting of Polo-like kinase-1 and Aurora kinases in T-cell acute lymphoblastic leukemia

artículo científico publicado en 2014

Two hits are better than one: targeting both phosphatidylinositol 3-kinase and mammalian target of rapamycin as a therapeutic strategy for acute leukemia treatment.

artículo científico publicado en 2012

Lista de obras de Camilla Evangelisti

Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 against T-cell acute lymphoblastic leukemia.

Advances in targeting signal transduction pathways

Advances in understanding the acute lymphoblastic leukemia bone marrow microenvironment: From biology to therapeutic targeting

Alteration of Akt activity increases chemotherapeutic drug and hormonal resistance in breast cancer yet confers an achilles heel by sensitization to targeted therapy

Autophagy in acute leukemias: a double-edged sword with important therapeutic implications

Current treatment strategies for inhibiting mTOR in cancer

Cytotoxic activity of the novel Akt inhibitor, MK-2206, in T-cell acute lymphoblastic leukemia.

DGKζ is degraded through the cytoplasmic ubiquitin-proteasome system under excitotoxic conditions, which causes neuronal apoptosis because of aberrant cell cycle reentry.

GSK-3β: a key regulator of breast cancer drug resistance

Identification of a functional nuclear export sequence in diacylglycerol kinase-zeta.

Improving nelarabine efficacy in T cell acute lymphoblastic leukemia by targeting aberrant PI3K/AKT/mTOR signaling pathway

Increased NGAL (Lnc2) expression after chemotherapeutic drug treatment.

Modulation of TGFbeta 2 levels by lamin A in U2-OS osteoblast-like cells: understanding the osteolytic process triggered by altered lamins

Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response

Nuclear diacylglycerol kinase-zeta is a negative regulator of cell cycle progression in C2C12 mouse myoblasts

Nuclear inositol lipid metabolism: more than just second messenger generation?

Nuclear phosphoinositides and their roles in cell biology and disease

PI3K isoform inhibition associated with anti Bcr-Abl drugs shows in vitro increased anti-leukemic activity in Philadelphia chromosome-positive B-acute lymphoblastic leukemia cell lines

PI3K/AKT/mTORC1 and MEK/ERK signaling in T-cell acute lymphoblastic leukemia: new options for targeted therapy

Phosphatidylinositol 3-kinase inhibition potentiates glucocorticoid response in B-cell acute lymphoblastic leukemia

Phosphoinositide 3-kinase/Akt signaling pathway and its therapeutical implications for human acute myeloid leukemia.

Potential therapeutic effects of the MTOR inhibitors for preventing ageing and progeria-related disorders

Preclinical testing of the Akt inhibitor triciribine in T-cell acute lymphoblastic leukemia.

Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance

Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health

Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging

Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance

Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy.

Subnuclear localization and differentiation-dependent increased expression of DGK-zeta in C2C12 mouse myoblasts.

Synergistic cytotoxic effects of bortezomib and CK2 inhibitor CX-4945 in acute lymphoblastic leukemia: turning off the prosurvival ER chaperone BIP/Grp78 and turning on the pro-apoptotic NF-κB.

TIS21/BTG2/PC3 and cyclin D1 are key determinants of nuclear diacylglycerol kinase-zeta-dependent cell cycle arrest

Targeted inhibition of mTORC1 and mTORC2 by active-site mTOR inhibitors has cytotoxic effects in T-cell acute lymphoblastic leukemia.

Targeting Wnt/β-catenin and PI3K/Akt/mTOR pathways in T-cell acute lymphoblastic leukemia

Targeting phosphatidylinositol 3-kinase signaling in acute myelogenous leukemia

Targeting signaling pathways in T-cell acute lymphoblastic leukemia initiating cells

Targeting the PI3K/AKT/mTOR signaling network in acute myelogenous leukemia

Targeting the RAF/MEK/ERK, PI3K/AKT and p53 pathways in hematopoietic drug resistance.

Targeting the cancer initiating cell: the ultimate target for cancer therapy.

Targeting the liver kinase B1/AMP-activated protein kinase pathway as a therapeutic strategy for hematological malignancies

Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway

The Cutting Edge: The Role of mTOR Signaling in Laminopathies

The Unfolded Protein Response: A Novel Therapeutic Target in Acute Leukemias

The emerging multiple roles of nuclear Akt

The emerging role of the phosphatidylinositol 3-kinase/ akt/mammalian target of rapamycin signaling network in cancer stem cell biology

The emerging role of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin signaling network in normal myelopoiesis and leukemogenesis.

The insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 induces apoptosis in acute myeloid leukemia cells exhibiting autocrine insulin-like growth factor-I secretion

The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients.

Therapeutic Targeting of mTOR in T-Cell Acute Lymphoblastic Leukemia: An Update

Therapeutic potential of targeting mTOR in T-cell acute lymphoblastic leukemia (review).

Therapeutic targeting of Polo-like kinase-1 and Aurora kinases in T-cell acute lymphoblastic leukemia

Two hits are better than one: targeting both phosphatidylinositol 3-kinase and mammalian target of rapamycin as a therapeutic strategy for acute leukemia treatment.